60 Degrees Pharma enrolls first patient in tafenoquine babesiosis trial in US Northeast hospitals

60 Degrees

60 Degrees

SXTP

0.00
  • 60 Degrees Pharmaceuticals enrolled the first 2026 seasonal patient in a placebo-controlled hospital trial testing tafenoquine as an add-on babesiosis treatment.
  • No efficacy results have been presented; an interim analysis is expected once at least 24 patients are enrolled, potentially as soon as early July 2026.
  • Enrollment is running about one month ahead of plan, supporting a faster read on whether tafenoquine improves symptom resolution or parasite clearance.
  • Tafenoquine is marketed as ARAKODA for malaria prevention, not for babesiosis, leaving the program dependent on clinical data to support expansion.
  • A timing update for the interim analyses is planned about 50 days after enrollment is completed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260802PRIMZONEFULLFEED9726086) on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.